odf3b Antibody

What is ODF3B and why is it significant for brain tumor research?

ODF3B is a protein-coding gene located in multiple cellular compartments including the nucleus, cytoskeleton, cytosol, and mitochondria. It has gained significant research interest due to its high expression in brain tissue and esophagus . Recent studies have revealed that ODF3B expression is positively correlated with glioma grade, with higher expression indicating worse prognosis . The protein has been identified as potentially functioning as a cancerous testicular antigen related to the development of central nervous system tumors . Most importantly, research has demonstrated that ODF3B affects glioma proliferation and apoptosis via the JAK/STAT pathway, positioning it as a promising therapeutic target for glioma treatment .

What are the molecular characteristics of ODF3B that researchers should understand?

ODF3B (also known as FAP123, ODF3L3) is encoded by a protein-coding gene with ID 440836 . The protein has several synonyms including "orf2 5' to PD-ECGF/TP," "outer dense fiber protein 3B," and "outer dense fiber protein 3-like protein 3" . Current research suggests that ODF3B functions within the JAK-STAT signaling pathway, which is involved in critical biological processes including cell growth, apoptosis, and immune regulation . When analyzing experimental results, researchers should be aware that ODF3B expression correlates with several clinical parameters, including patient age (higher expression in patients >40 years), IDH mutation status (positively correlated with IDH wild-type), and 1p19q co-deletion status (higher expression in groups without co-deletion) .

How does ODF3B expression vary across normal and pathological states?

In normal conditions, ODF3B is highly expressed in brain tissue and esophagus, suggesting tissue-specific functions . In pathological states, particularly glioma, ODF3B shows significantly elevated expression compared to normal brain tissue . Expression analysis across databases (TCGA, CGGA) and clinical samples has consistently demonstrated that ODF3B is highly expressed in both glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with particularly high expression in GBM . This expression pattern appears to be maintained across various glioma cell lines including U87-MG, U373, U251, LN229, A172, and T98, all showing elevated ODF3B at both mRNA and protein levels compared to normal brain cell line NHA .

What are the recommended applications for ODF3B antibodies in glioma research?

Based on current research protocols, ODF3B antibodies have been successfully employed in several key applications:

For optimal results, researchers should verify antibody specificity via knockdown controls and use appropriate positive control tissues (such as brain samples) for validation .

How should researchers optimize Western blot protocols for ODF3B detection?

For robust detection of ODF3B via Western blot, researchers should follow these optimization steps:

• Sample preparation: Use tissue or cell lysates with proper protease inhibitors to prevent degradation

• Protein loading: 35μg/lane has been demonstrated to provide sufficient signal for detection in mouse heart tissue lysates

• Antibody selection: N-terminal targeting antibodies have shown good specificity for ODF3B detection

• Controls: Include both positive controls (brain tissue) and negative controls

• Visualization: Look for a distinct band at the expected molecular weight for ODF3B

• Validation: Confirm specificity through knockdown experiments in relevant cell lines (U87-MG and U373 have shown high ODF3B expression and are good candidates)

When troubleshooting, consider that ODF3B expression may vary across tissues and cell types, requiring adjustment of protein loading and exposure times.

What cell and tissue models are most appropriate for studying ODF3B function?

Based on published research, the following models have demonstrated utility for ODF3B investigations:

When designing experiments, consider that ODF3B expression is positively correlated with glioma grade, so different cell models may exhibit varying baseline expression levels .

How should researchers interpret changes in ODF3B expression across different glioma grades?

When analyzing ODF3B expression across glioma specimens, researchers should consider:

These patterns suggest that ODF3B quantification may have potential prognostic value and could help stratify patients for targeted therapies.

What methods can validate the specificity of ODF3B antibody signals?

To ensure reliable results, researchers should implement multiple validation approaches:

• Genetic validation: Using shRNA knockdown (sh2-ODF3B has shown high knockdown efficiency in glioma cell lines)

• Molecular weight verification: Confirming band size in Western blot corresponds to expected ODF3B molecular weight

• Signal pattern analysis: Verifying subcellular localization matches known distribution (nucleus, cytoskeleton, mitochondria)

• Antibody comparison: Testing multiple antibodies targeting different epitopes (e.g., N-terminal vs. C-terminal regions)

• Positive and negative tissue controls: Using tissues with known high (brain) and low ODF3B expression

• Correlation analysis: Comparing protein detection with mRNA levels via RT-qPCR

This multi-faceted validation approach helps distinguish specific signals from potential artifacts and ensures experimental robustness.

How can researchers appropriately control for ODF3B antibody experiments?

A comprehensive control strategy should include:

Implementing these controls provides confidence in experimental results and helps troubleshoot potential technical issues.

How can researchers investigate the relationship between ODF3B and the JAK/STAT pathway?

To explore the ODF3B-JAK/STAT pathway connection, researchers should consider these methodologies:

• Phosphorylation analysis: Western blot assessment of p-JAK1, p-JAK2, and p-STAT3 following ODF3B manipulation (knockdown demonstrably reduces phosphorylation of these proteins)

• Pathway modulation: Using JAK/STAT activators like Colivelin TFA to verify pathway dependence (this approach has successfully rescued proliferation and anti-apoptotic effects in ODF3B-knockdown cells)

• Expression correlation: KEGG pathway analysis has shown ODF3B expression correlates with JAK-STAT signaling pathway components

• Functional rescue experiments: Testing whether JAK/STAT activation can restore proliferation capacity in ODF3B-knockdown cells (demonstrated successfully in U87-MG and U373 models)

• Protein interaction studies: Investigating whether ODF3B directly interacts with JAK/STAT components

These approaches can help elucidate the precise mechanism by which ODF3B influences glioma cell proliferation and apoptosis through JAK/STAT signaling.

What experimental approaches can assess ODF3B as a therapeutic target?

To evaluate ODF3B's potential as a therapeutic target, researchers should implement:

• In vitro functional assessment:

  • Cell viability assays following ODF3B knockdown (demonstrated significant reduction in proliferation)

  • Colony formation assays (ODF3B knockdown reduces colony-forming ability)

  • Apoptosis assays (Annexin V-FITC/PI detection shows increased apoptosis after ODF3B knockdown)

• Molecular mechanism exploration:

  • Analysis of apoptosis-related proteins (Bcl2 decreases and cleaved-caspase 3 increases after ODF3B knockdown)

  • JAK/STAT pathway component evaluation via Western blot

• In vivo validation:

  • Orthotopic implantation models (ODF3B knockdown inhibits tumor formation and extends survival)

  • Immunohistochemical analysis of tumor sections for apoptosis markers

• Combination approaches:

  • Testing ODF3B targeting with existing JAK/STAT inhibitors

  • Exploring synergistic effects with standard-of-care treatments

These multi-level approaches provide comprehensive evaluation of ODF3B as a potential therapeutic target for glioma treatment.

How can researchers design advanced experiments to explore ODF3B's role in IDH-mutant versus wild-type gliomas?

Given the correlation between ODF3B expression and IDH status , researchers can design experiments to further investigate this relationship:

• Comparative expression analysis:

  • Stratify patient samples by IDH mutation status

  • Quantify ODF3B expression at protein and mRNA levels

  • Correlate with clinical outcomes in each subgroup

• Functional implications:

  • Compare effects of ODF3B knockdown in IDH-mutant versus wild-type cell lines

  • Assess differential impact on JAK/STAT pathway activation

  • Evaluate changes in proliferation, apoptosis, and invasion potential

• Metabolic connections:

  • Investigate whether IDH-associated metabolic changes influence ODF3B expression

  • Assess whether 2-hydroxyglutarate (2-HG) production affects ODF3B function

  • Explore potential epigenetic regulation through IDH-mediated DNA methylation

• Therapeutic sensitivity:

  • Determine if ODF3B expression affects response to IDH-targeted therapies

  • Evaluate whether combined targeting of ODF3B and IDH pathways enhances efficacy

This stratified approach would provide insights into whether ODF3B functions differently in molecular subgroups of glioma, potentially revealing context-specific therapeutic opportunities.

How might single-cell analysis techniques advance understanding of ODF3B in tumor heterogeneity?

Single-cell approaches offer new opportunities to understand ODF3B's role in tumor heterogeneity:

• Single-cell RNA sequencing (scRNA-seq):

  • Map ODF3B expression across distinct cellular populations within gliomas

  • Identify cell types with highest ODF3B expression

  • Correlate with JAK/STAT pathway activation at single-cell resolution

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) to simultaneously measure ODF3B and phosphorylated JAK/STAT proteins

  • Single-cell Western blot for protein-level heterogeneity assessment

• Spatial transcriptomics:

  • Map ODF3B expression patterns within the tumor microenvironment

  • Correlate with invasive fronts versus tumor core regions

  • Assess relationship to hypoxic regions and vascular structures

• Clonal evolution analysis:

  • Track changes in ODF3B expression during tumor progression and treatment

  • Determine if ODF3B-high clones show differential treatment resistance

These approaches would help identify whether ODF3B expression defines specific cellular subpopulations that might require targeted therapeutic strategies.

What considerations are important when developing antibodies for ODF3B detection in clinical applications?

For clinical translation of ODF3B antibodies, researchers should consider:

• Epitope selection:

  • N-terminal targeting has shown effectiveness in research applications

  • Multiple epitope antibodies may provide comprehensive detection

• Format optimization:

  • Monoclonal antibodies offer reproducibility advantages for clinical use

  • Rabbit-derived antibodies have demonstrated good specificity

• Validation requirements:

  • Extensive testing across diverse patient samples

  • Comparison against established diagnostic/prognostic markers

  • Correlation with molecular subtypes (IDH status, 1p19q co-deletion)

• Standardization protocols:

  • Consistent immunohistochemistry methods for reproducible scoring

  • Digital pathology approaches for quantitative assessment

  • Quality control procedures for clinical laboratory implementation

• Clinical utility assessment:

  • Prognostic value verification in prospective trials

  • Predictive capability for treatment response

  • Integration with existing molecular classification systems

Careful consideration of these factors would support transition from research applications to potential clinical diagnostic or prognostic use.

How can computational approaches enhance antibody-based ODF3B research?

Advanced computational methods can significantly extend antibody-based ODF3B investigations:

• Structural biology and antibody design:

  • Computational prediction of ODF3B protein structure

  • Structure-based epitope mapping for optimal antibody targeting

  • De novo design approaches for high-affinity antibody variable regions

• Image analysis enhancement:

  • Machine learning algorithms for automated quantification of ODF3B immunostaining

  • Deep learning for correlation between ODF3B expression patterns and clinical outcomes

  • Computer vision techniques for subcellular localization analysis

• Network biology:

  • Pathway and network analysis to position ODF3B within broader signaling contexts

  • Identification of potential co-targeting opportunities through network analysis

  • Integration of proteomic and transcriptomic data for comprehensive pathway mapping

• Clinical data integration:

  • Multivariate models incorporating ODF3B expression with clinical parameters

  • Predictive algorithms for patient stratification

  • Biomarker signature development that includes ODF3B

These computational approaches could accelerate discovery and translation of ODF3B-related findings while ensuring robust and reproducible research outcomes.